MARKET

PROG

PROG

PROGENITY, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9000
-0.0544
-5.70%
After Hours: 0.9100 +0.01 +1.11% 19:57 09/24 EDT
OPEN
0.9609
PREV CLOSE
0.9544
HIGH
0.9609
LOW
0.9000
VOLUME
3.99M
TURNOVER
--
52 WEEK HIGH
9.56
52 WEEK LOW
0.6570
MARKET CAP
40.65M
P/E (TTM)
-0.2598
1D
5D
1M
3M
1Y
5Y
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11 annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston.
GlobeNewswire · 3d ago
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 3d ago
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 4d ago
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 4d ago
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and by region.
AmericaNewsHour · 4d ago
What Is The Ownership Structure Like For Progenity, Inc. (NASDAQ:PROG)?
If you want to know who really controls Progenity, Inc. ( NASDAQ:PROG ), then you'll have to look at the makeup of its...
Simply Wall St. · 09/14 14:41
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 14, 2021: LEN, LICD, HLF, NNVC, PROG
Today's 5 Stock Ideas:  Lennar Corp (LEN) - Lennar reports Q3 earnings on Monday, September 20th. Lucid Group (LCID) - Shares down ~4.40% premarket. Morgan Stanley initiated coverage on the stock
Benzinga · 09/14 12:56
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia
Benzinga · 09/14 11:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PROG. Analyze the recent business situations of PROGENITY, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PROG stock price target is 7.00 with a high estimate of 12.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 55.05M
% Owned: 121.88%
Shares Outstanding: 45.16M
TypeInstitutionsShares
Increased
10
14.73M
New
16
1.97M
Decreased
12
1.19M
Sold Out
22
3.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.19%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chief Executive Officer/Chief Financial Officer
Eric d'Esparbes
Chief Operating Officer
Damon Silvestry
Senior Vice President/Director of Sales
George Gianakopoulos
Chief Information Officer
Troy Seelye
Chief Scientific Officer
Matthew Cooper
Chief Compliance Officer
Hutan Hashemi
General Counsel/Secretary
Clarke Neumann
Other
Sami Shihabi
Lead Director
Jeffrey Alter
Director
Surbhi Sarna
Independent Director
Jeffrey Ferrell
Independent Director
Brian Kotzin
Independent Director
Samuel Nussbaum
Independent Director
Lynne Powell
No Data
About PROG
Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products and precision medicine. It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. It offers integrated molecular tests and end-to-end support services that enable physicians to incorporate genetic testing into their office workflow and enables in ordering multiple tests from one source. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, Resura Prenatal Test for Monogenic Disease, and Anatomic and Molecular Pathology Tests. It is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.

Webull offers kinds of Progenity Inc stock information, including NASDAQ:PROG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PROG stock methods without spending real money on the virtual paper trading platform.